MoonLake Immunotherapeut... Stock Quote MLTX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

48.83

Bid

38.00

Ask

98.00

Volume

0.00 Day's Range 0.00

37.55 52 Week Range 64.98

Market Cap

3.12B

Previous Close

48.83

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

315,088

Shares Outstanding

63,905,198

Dividend Yield

PE Ratio

-70.79

Earnings Per Share (EPS)

-0.69

Revenue

Net Profit

-44.08M

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Sector

Blank Checks

Industry

Pharmaceutical Preparations

Website

moonlaketx.com

Headquarters

Grand Cayman, Cym

Founded

2020

MoonLake Immunotherapeutics is listed in the Blank Checks sector of the NASDAQ with ticker MLTX. The last closing price for MoonLake Immunotherapeut... was $48.83. Over the last year, MoonLake Immunotherapeut... shares have traded in a share price range of $ 37.55 to $ 64.98.

MoonLake Immunotherapeut... currently has 63,905,198 shares outstanding. The market capitalization of MoonLake Immunotherapeut... is $3.12 billion. MoonLake Immunotherapeut... has a price to earnings ratio (PE ratio) of -70.79.

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing...

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-3.17	-6.09615384615	52	54.81	48.3	238388	51.30942133	CS
4	-0.04	-0.0818498056067	48.87	54.81	45.24	234290	48.91331069	CS
12	0.51	1.05546357616	48.32	56	44.71	315088	50.43126095	CS
26	9.22	23.2769502651	39.61	56	37.55	329457	46.45758206	CS
52	6.15	14.4095595127	42.68	64.98	37.55	399972	49.1949626	CS
156	36.46	294.745351657	12.37	64.98	4.25	350020	42.80486129	CS
260	36.46	294.745351657	12.37	64.98	4.25	350020	42.80486129	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	$ 14.39 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 64.84 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.11 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.39 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 64.84 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.11 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.39 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 64.84 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.11 (0.00%)	0
AACGATA Creativity Global	$ 1.01 (0.00%)	0